Project Grant W81XWH2210753

This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai aims to develop a novel single-cell multi-omic profiling method called SHARE-ME-SEQ. This method will jointly capture gene expression, chromatin accessibility, and DNA methylation at the single-cell level to provide unprecedented insights into the regulatory mechanisms underlying cancer cell plasticity and metastasis, with a focus on acute myeloid...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $230,010 to the University of Chicago to conduct research aimed at understanding the drivers of metastasis in small cell lung cancer (SCLC). The project leverages the university's recently developed method to generate functionally viable pulmonary neuroendocrine cells (PNECs) from human pluripotent stem cells, which can be transformed to replicate key stages of SCLC from...

This $631,156 federal Project Grant award from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover core mechanisms facilitating lineage plasticity (LP) in EGFR-mutant lung cancer. The award to the Icahn School of Medicine at Mount Sinai aims to systematically define the epigenetic, transcriptional, and molecular drivers of the transition from lung adenocarcinoma (LUAD) to the more aggressive small cell lung...

The National Cancer Institute (NCI) awarded a Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to The Regents of the University of California, San Francisco (UCSF) totaling $679,188. The grant will fund the development of liquid biopsy tests using artificial intelligence-assisted, morphology-based isolation of tumor cells from malignant effusions to evaluate known actionable breast cancer biomarkers and discover new predictive molecular and morphology-based...

The National Cancer Institute (NCI) awarded a $256,487 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research in New York, NY. The purpose of this 5-year grant is to develop multimodal predictive models that integrate real-world data from circulating tumor DNA (ctDNA) sequencing, radiomics, tumor registries, and tissue genomics to improve risk stratification and clinical management of non-small cell lung cancer (NSCLC). The...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $2,078,214 to Precision Epigenomics Inc., a University of Arizona spin-out company, to conduct a multi-site clinical validation study for their Sentinel-MPE liquid biopsy assay. The Sentinel-MPE test aims to accurately diagnose malignant pleural effusions, which currently have limited sensitivity using conventional cytology methods. The project has two key objectives: 1)...

The National Cancer Institute (NCI) awarded a $122,032 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Weill Medical College of Cornell University. The grant, with a project period from February 1, 2025 to January 31, 2027, aims to explore the role of aberrant splicing in cancer cell heterogeneity and its potential as targets for novel immunotherapeutic strategies. The research will utilize advanced computational frameworks and multimodal single-cell approaches to...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $696,447 to the Rector & Visitors of the University of Virginia to develop and evaluate a SPECT imaging and targeted alpha therapy approach for treating mesothelioma, a deadly form of cancer. The project aims to target a tumor-specific CD46 epitope using a novel human monoclonal antibody for both diagnostic imaging with 203Pb and targeted radiotherapy with 212Pb,...

This federal Project Grant award of $531,379, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mitochondrial networks as a critical determinant of response to antibody drug conjugates (ADCs) in advanced/metastatic non-small cell lung cancer (NSCLC). The primary goals of this 5-year study are to: 1) Investigate baseline mitochondrial network architecture as a critical factor influencing NSCLC response to ADCs with the DXD...

The National Cancer Institute (NCI) awarded a $554,653 Project Grant under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to the Institute for Systems Biology (ISB) to develop "RARECYTEFINDER", a label-free method for the unbiased identification and molecular analysis of rare disseminated tumor cells (DTCs) in liquid and tissue biopsies. The grant aims to create an advanced, genome-wide copy number-based approach to overcome limitations of current DTC detection...